X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Guest post: Hearing from patients on Rare Disease Day

By Guest Contributor  |    February 28, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation

By Richard Moscicki, M.D.  |    February 28, 2019
Today is Rare Disease Day, an annual reminder of the incredible community of patients living with a rare disease. In the U.S., rare diseases are classified as conditions that affect fewer than...   Read More

Fact Check: Biologics, regulatory data protection and the United States-Mexico-Canada Agreement

By Douglas Petersen  |    February 27, 2019
There are a lot of misconceptions and inaccuracies going around about the United States-Mexico-Canada Agreement (USMCA) and its implications for biopharmaceutical innovation and medicine prices. Some...   Read More

New data show how sharing negotiated discounts could save certain patients hundreds of dollars at the pharmacy counter

By Tiffany Haverly  |    February 25, 2019
Updated 3/5/2019 Ensuring patients receive already negotiated savings on their medicines could save certain patients across seven states up to $2,360 a year, according to new analyses from Milliman.   Read More

GOBOLDLY ad showcases need to foster America’s leadership in medical innovation

By Holly Campbell  |    February 25, 2019
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released Breakthrough, the latest chapter of GOBOLDLY advertising showcasing the extraordinary medical breakthroughs being...   Read More

Look at the facts. Drug importation is dangerous.

By Nicole Longo  |    February 22, 2019
Today, 1 in 10 medicines worldwide and up to 50 percent of drugs consumed in developing nations are counterfeit. Importation proposals would open the U.S. borders to these dangerous and potentially...   Read More

What you need to know about the new NHE health spending projections

By Holly Campbell  |    February 22, 2019
This week, National Health Expenditure (NHE) data released by the Centers for Medicare & Medicaid Services (CMS) projected retail medicine spending grew 3.3 percent in 2018. Each year, CMS projects...   Read More

Guest post: Copay accumulator adjustment programs lead to four times higher treatment discontinuation for patients with high deductibles

By Guest Contributor  |    February 21, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

130 medicines in development for asthma, allergies and other respiratory diseases

By Andrew Powaleny  |    February 21, 2019
Millions of Americans suffer from respiratory diseases, including Asthma and chronic obstructive pulmonary disease (COPD). Together, these two diseases affect the day-to-day lives of over 40 million...   Read More

Value assessments should include all the outcomes that matter to patients and families

By Katie Koziara  |    February 20, 2019
Value assessments are an important tool in moving toward better, more affordable health care. When it comes to assessing the value of medicines, we need approaches that reflect what matters to...   Read More

New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis

By Holly Campbell  |    February 14, 2019
New research by three Milliman actuaries explores the dynamics underlying the relationship between Medicare Part D plan premiums and sharing rebates directly with beneficiaries at the pharmacy...   Read More

Why vaccines work in the fight against measles and other infectious diseases

By Richard Moscicki, M.D.  |    February 13, 2019
It is often said that vaccines are only second to clean drinking water in terms of public health impact. In recent years, misinformation about vaccines, especially childhood vaccinations, has spread...   Read More

Combatting Opioid Abuse: Joint Partnership with the Rx Abuse Leadership Initiative and The National Sheriffs’ Association

By Priscilla VanderVeer  |    February 12, 2019
The National Sheriffs’ Association (NSA) recently partnered with the Rx Abuse Leadership Initiative (RALI), a dynamic alliance of organizations dedicated to finding solutions to the opioid crisis...   Read More

Biopharmaceutical venture capital is spurring innovation and economic growth

By Tim McClung  |    February 11, 2019
The biopharmaceutical ecosystem has helped make the U.S. the global leader in biomedical innovation today. An important part of this ecosystem is the thousands of small startup biopharmaceutical...   Read More

Why state drug importation pilot programs don’t work

By Nick McGee  |    February 8, 2019
Across the country, some states are recirculating failed proposals that would establish state-run prescription medicine importation schemes. Such proposals would allow medicines from foreign...   Read More

In survey, PhRMA member companies highlight impact of IPI on R&D

By Katie Verb  |    February 5, 2019
One of the biggest myths regarding the administration’s proposed International Pricing Index (IPI) Model is that it will have little to no effect on biomedical research and development (R&D)....   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."